Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Siemens Healthineers AG (SHL.DE)
Forchheim, DE
Siemens Healthineers AG, a subsidiary of Siemens Aktiengesellschaft with its headquarters in Erlangen, Germany, is a global leader in medical technology. The company develops, produces, and distributes a comprehensive portfolio of diagnostic and therapeutic products and services, catering to healthcare providers worldwide. Its operations are organized into four distinct business segments. The Imaging segment delivers advanced medical imaging systems, encompassing magnetic resonance imaging (MRI), computed tomography (CT), X-ray technology, molecular imaging, and ultrasound solutions. The Diagnostics segment focuses on providing in-vitro diagnostic products and services for laboratory, molecular, and point-of-care applications, alongside workflow optimization tools and informatics solutions for healthcare facilities. Varian, another key segment, specializes in cancer care, offering cutting-edge technologies, services, and integrated solutions to hospital oncology departments. This includes enhancing workflow efficiency, providing clinical services and consulting, and deploying digital platforms for treatment and therapy management. Lastly, the Advanced Therapies segment supplies sophisticated products designed to facilitate image-guided minimally invasive treatments across various medical fields, such as cardiology, interventional radiology, and surgery. Its offerings include angiography systems, mobile C-arms, and a robotic-assisted platform specifically for endovascular coronary and peripheral vascular procedures. Beyond these core offerings, Siemens Healthineers also provides a suite of essential support services, such as equipment performance management, clinical education and e-learning programs, asset management, managed departmental services for laboratories and healthcare facilities, and expert consulting and digital health services.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.98% | -2.05% | -10.25% | -16.01% | -24.36% | -23.96% | -30.52% | -36.94% | -26.10% | +12.25% | +12.25% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 4 | 0 |
| Buy | 11 | 0 |
| Hold | 5 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Medical - Devices: +11.2%+4.5% Q1'26: -3.9% (vs Q1'25)
-
EPS growth Medical - Devices: +28.5%+10.4% Q1'26: -4.3% (vs Q1'25)
-
FCF margin FCF growth · Medical - Devices: +30.9%+8.9% Q1'26: +4.8% (vs Q1'25)
-
EBIT margin Medical - Devices: +6.2%+14.1% ★ Q1'26: +13.3% (vs Q1'25)
-
ROIC Medical - Devices: +3.3%+8.1% ★ Q1'26: +7.6% (vs Q1'25)
-
Share dilution Medical - Devices: 0.0%+0.1% Q1'26: -0.4% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Devices: -0.35×3.29× Q1'26: 3.78× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Sep 2018 actual |
Sep 2019 actual |
Sep 2020 actual |
Sep 2021 actual |
Sep 2022 actual |
Sep 2023 actual |
Sep 2024 actual |
Sep 2025 actual |
Sep 2026 17 Rev. Ana. 11 EPS Ana. |
Sep 2027 18 Rev. Ana. 14 EPS Ana. |
Sep 2028 16 Rev. Ana. 9 EPS Ana. |
Sep 2029 8 Rev. Ana. 6 EPS Ana. |
Sep 2030 8 Rev. Ana. 7 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
13.43B
est: 13.48B (-0.4%)
|
14.52B
est: 14.33B (+1.3%)
|
14.46B
est: 14.53B (-0.5%)
|
18.00B
est: 17.83B (+1.0%)
|
21.71B
est: 21.40B (+1.5%)
|
21.68B
est: 21.87B (-0.9%)
|
22.36B
est: 22.41B (-0.2%)
|
23.38B
est: 23.51B (-0.6%)
|
23.85B
23.56B – 24.35B
+1.4% YoY
|
25.32B
24.98B – 26.09B
+6.1% YoY
|
26.86B
26.84B – 26.88B
+6.1% YoY
|
28.48B
28.11B – 29.21B
+6.0% YoY
|
30.29B
29.90B – 31.07B
+6.4% YoY
|
| EBITDA |
2.53B
est: 2.56B (-1.4%)
|
2.93B
est: 2.27B (+29.2%)
|
2.84B
est: 2.79B (+1.9%)
|
3.52B
est: 2.97B (+18.7%)
|
4.26B
est: 3.18B (+33.9%)
|
3.78B
est: 4.16B (-9.2%)
|
4.22B
est: 4.28B (-1.2%)
|
4.58B
est: 4.47B (+2.5%)
|
4.54B
4.48B – 4.63B
+1.4% YoY
|
4.82B
4.75B – 4.96B
+6.1% YoY
|
5.11B
5.10B – 5.11B
+6.1% YoY
|
5.42B
5.35B – 5.56B
+6.0% YoY
|
5.76B
5.69B – 5.91B
+6.4% YoY
|
| EBIT |
2.00B
est: 1.75B (+14.1%)
|
2.31B
est: 2.07B (+11.8%)
|
2.03B
est: 2.36B (-14.1%)
|
2.48B
est: 2.51B (-1.2%)
|
2.92B
est: 2.69B (+8.4%)
|
2.22B
est: 3.13B (-29.2%)
|
3.00B
est: 3.22B (-6.9%)
|
3.29B
est: 3.37B (-2.4%)
|
3.42B
3.38B – 3.49B
+1.4% YoY
|
3.63B
3.58B – 3.74B
+6.1% YoY
|
3.85B
3.85B – 3.85B
+6.1% YoY
|
4.08B
4.03B – 4.19B
+6.0% YoY
|
4.34B
4.29B – 4.45B
+6.4% YoY
|
| Net Income |
1.27B
est: 1.67B (-24.1%)
|
1.57B
est: 1.33B (+17.5%)
|
1.41B
est: 1.61B (-12.5%)
|
1.73B
est: 1.71B (+0.7%)
|
2.04B
est: 1.84B (+10.9%)
|
1.51B
est: 1.84B (-18.0%)
|
1.94B
est: 2.50B (-22.2%)
|
2.14B
est: 2.71B (-20.9%)
|
2.57B
2.50B – 2.64B
-5.2% YoY
|
2.94B
2.76B – 3.11B
+14.4% YoY
|
2.96B
2.87B – 3.66B
+0.9% YoY
|
3.69B
3.63B – 3.81B
+24.4% YoY
|
4.14B
4.08B – 4.28B
+12.3% YoY
|
| SGA |
2.15B
est: 2.04B (+5.7%)
|
2.16B
est: 2.27B (-5.0%)
|
2.20B
est: 2.28B (-3.4%)
|
2.63B
est: 2.42B (+8.6%)
|
3.29B
est: 2.59B (+26.7%)
|
3.40B
est: 3.30B (+3.0%)
|
3.25B
est: 3.40B (-4.3%)
|
3.64B
est: 3.55B (+2.4%)
|
3.60B
3.56B – 3.68B
+1.4% YoY
|
3.82B
3.77B – 3.94B
+6.1% YoY
|
4.06B
4.05B – 4.06B
+6.1% YoY
|
4.30B
4.25B – 4.41B
+6.0% YoY
|
4.58B
4.52B – 4.69B
+6.4% YoY
|
| EPS |
1.27
est: 1.48 (-14.2%)
|
1.57
est: 1.67 (-5.9%)
|
1.41
est: 1.54 (-8.6%)
|
1.57
est: 2.04 (-22.9%)
|
1.82
est: 2.23 (-18.5%)
|
1.35
est: 1.65 (-18.1%)
|
1.74
est: 2.20 (-21.0%)
|
1.91
est: 2.39 (-20.1%)
|
2.28
2.22 – 2.35
-4.5% YoY
|
2.60
2.46 – 2.77
+14.0% YoY
|
2.94
2.55 – 3.25
+13.1% YoY
|
3.28
3.23 – 3.39
+11.5% YoY
|
3.68
3.62 – 3.81
+12.3% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-11 | B+ | 3/5 | 4/5 | 4/5 | 4/5 | 1/5 | 3/5 | 3/5 |
| 2026-05-08 | B+ | 3/5 | 4/5 | 4/5 | 4/5 | 1/5 | 2/5 | 3/5 |
| 2026-05-07 | B+ | 3/5 | 4/5 | 4/5 | 4/5 | 1/5 | 2/5 | 3/5 |
| 2026-05-06 | B+ | 3/5 | 4/5 | 4/5 | 4/5 | 1/5 | 2/5 | 3/5 |
| 2026-05-05 | B+ | 3/5 | 4/5 | 4/5 | 4/5 | 1/5 | 3/5 | 3/5 |
| 2026-05-04 | B+ | 3/5 | 4/5 | 4/5 | 4/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-30 | B+ | 3/5 | 4/5 | 4/5 | 4/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-29 | B+ | 3/5 | 4/5 | 4/5 | 4/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-28 | B+ | 3/5 | 4/5 | 4/5 | 4/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-27 | B+ | 3/5 | 4/5 | 4/5 | 4/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-24 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-23 | B+ | 3/5 | 4/5 | 4/5 | 5/5 | 1/5 | 2/5 | 3/5 |
| 2026-04-22 | B+ | 3/5 | 4/5 | 4/5 | 5/5 | 1/5 | 2/5 | 3/5 |
| 2026-04-21 | B+ | 3/5 | 4/5 | 4/5 | 5/5 | 1/5 | 2/5 | 3/5 |
| 2026-04-20 | B+ | 3/5 | 4/5 | 4/5 | 5/5 | 1/5 | 2/5 | 3/5 |
| 2026-04-17 | B+ | 3/5 | 4/5 | 4/5 | 5/5 | 1/5 | 2/5 | 3/5 |
| 2026-04-16 | B+ | 3/5 | 4/5 | 4/5 | 5/5 | 1/5 | 2/5 | 3/5 |
| 2026-04-15 | B+ | 3/5 | 4/5 | 4/5 | 5/5 | 1/5 | 2/5 | 3/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Bernhard Montag | President, Chief Executive Officer & Chairman of Management Board | 3M | — |
| Jochen Schmitz | Chief Financial Officer & Member of Management Board | 2M | — |
| Darleen Caron | Chief Human Resources Officer, Labor Director & Member of Management Board | 2M | female |
| Elisabeth Staudinger | Member of Management Board | 2M | female |
| Astrid Kristine Ploss | Member of Supervisory Board, Head of Legal Advanced Therapies & Head of Legal Technology Excellence | 71.0K | female |
| Matthias Kraemer | Head of Corporate Communications | — | — |
| Carsten Bertram | Head of Advanced Therapies | — | — |
| Christian Klaussner | Executive Vice President of Finance | — | — |
| Marc Koebernick | Head of Investor Relations | — | male |
| Andre Hartung | Head of Diagnostic Imaging | — | — |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for SHL.DE
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
